Pancreatic Cancer Clinical Trials in Beijing, Beijing Municipality
17 recruitingBeijing, Beijing Municipality, China
Showing 1–17 of 17 trials
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 1Phase 2
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.72 enrolled16 locationsNCT06821503
Recruiting
Not Applicable
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Pancreatic Cancer
Wu Wenming28 enrolled1 locationNCT06353646
Recruiting
Phase 1Phase 2
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Locally Advanced or Metastatic Pancreatic Cancer With
Shanghai Hengrui Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07296341
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
Pancreatic Cancer
Peking Union Medical College Hospital3,000 enrolled10 locationsNCT06375473
Recruiting
Phase 3
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.662 enrolled1 locationNCT07238283
Recruiting
Phase 1Phase 2
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
Pancreatic CancerPancreatic CarcinomaPancreatic Cancer Stage IV+1 more
Essen Biotech60 enrolled1 locationNCT07066995
Recruiting
Phase 1
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Breast CancerPancreatic CancerOvarian Cancer+1 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.318 enrolled1 locationNCT05740956
Recruiting
Phase 2
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.50 enrolled1 locationNCT06962267
Recruiting
Not Applicable
Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound
Pancreatic Cancer
Peking Union Medical College Hospital75 enrolled1 locationNCT05617872
Recruiting
Phase 2
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Pancreatic Cancer
Akeso78 enrolled7 locationsNCT05859750
Recruiting
Phase 2
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
Borderline Resectable Pancreatic Cancer
Peking Union Medical College Hospital45 enrolled1 locationNCT06387810
Recruiting
Phase 1
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Pancreatic Cancer
CARsgen Therapeutics Co., Ltd.20 enrolled8 locationsNCT05911217
Recruiting
Phase 3
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.778 enrolled1 locationNCT05751850
Recruiting
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123
Recruiting
Phase 2Phase 3
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
Metastatic Pancreatic Cancer
1Globe Health Institute LLC336 enrolled38 locationsNCT03721744
Recruiting
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
Liver CancerPancreatic CancerLung Cancer+1 more
Peking University Third Hospital57 enrolled1 locationNCT06342323